Axsome Therapeutics, Inc.·4

Feb 25, 7:59 PM ET

Saad Mark E 4

4 · Axsome Therapeutics, Inc. · Filed Feb 25, 2025

Insider Transaction Report

Form 4
Period: 2025-02-21
Saad Mark E
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-02-21+1,4941,494 total
    Exercise: $137.75From: 2025-02-21Exp: 2035-02-20Common Stock (1,494 underlying)
Footnotes (1)
  • [F1]Represents 1,494 options elected to be received in lieu of cash compensation earned in 2024. All of such options are immediately exercisable.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4